The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial

The Lancet

Volumn 377, Issue 9784, 2011, Pages 2181-2192

  Baigent, Colin ^a,ad   Landray, Martin J ^a   Reith, Christina ^a   Emberson, Jonathan ^a   Wheeler, David C ^b   Tomson, Charles ^c   Wanner, Christoph ^d   Krane, Vera ^d   Cass, Alan ^e   Craig, Jonathan ^f   Neal, Bruce ^e   Jiang, Lixin ^g   Hooi, Lai Seong ^h   Levin, Adeera ⁱ   Agodoa, Lawrence ^j   Gaziano, Mike ^k   Kasiske, Bertram ^l   Walker, Robert ^m   Massy, Ziad A ⁿ   Feldt Rasmussen, Bo ^o   Krairittichai, Udom ^p   Ophascharoensuk, Vuddidhej ^q   Fellström, Bengt ^r   Holdaas, Hallvard ^s   Tesar, Vladimir ^t   Wiecek, Andrzej ^u   Grobbee, Diederick ^v   De Zeeuw, Dick ^w   Grönhagen Riska, Carola ^x   Dasgupta, Tanaji ^y   Lewis, David ^a   Herrington, William ^a   Mafham, Marion ^a   Majoni, William ^z   Wallendszus, Karl ^a   Grimm, Richard ^l   Pedersen, Terje ^aa   Tobert, Jonathan ^ab   Armitage, Jane ^a   Baxter, Alex ^a   Bray, Christopher ^a   Chen, Yiping ^a   Chen, Zhengming ^a   Hill, Michael ^a   Knott, Carol ^a   Parish, Sarah ^a   Simpson, David ^a   Sleight, Peter ^ac   Young, Alan ^a   Collins, Rory ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g FUWAI HOSPITAL   (China)

^h HOSPITAL SULTANAH AMINAH   (Malaysia)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m UNIVERSITY OF OTAGO   (New Zealand)

ⁿ AMIENS UNIVERSITY HOSPITAL   (France)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

^p RAJAVITHI HOSPITAL   (Thailand)

^q Faculty of Medicine Chiang Mai University   (Thailand)

^r UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^s OSLO UNIVERSITY HOSPITAL   (Norway)

^t CHARLES UNIVERSITY   (Czech Republic)

^u MEDICAL UNIVERSITY OF SILESIA   (Poland)

^v UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^w UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^x HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^y OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^z ROYAL DARWIN HOSPITAL   (Australia)

^aa UNIVERSITY OF OSLO   (Norway)

^ab Tobert Medical Consulting LLC   (United States)

^ac JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^ad CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CANCER RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CREATINE KINASE BLOOD LEVEL; CREATININE URINE LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GALLSTONE; HEART INFARCTION; HEMODIALYSIS; HEPATITIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEOPLASM; PANCREATITIS; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

EID: 79959746706     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60739-3     Document Type: Article

References (26)

1. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 2010 2073 2081
2. RN Foley, PS Parfrey, MJ Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 suppl 3 1998 S112 S119
3. National Kidney Foundation K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease Am J Kidney Dis 41 suppl 3 2003 S1 91
4. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
5. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
6. M Tonelli, C Isles, GC Curhan et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 2004 1557 1563 (Pubitemid 39297976)
7. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
8. The SEARCH Collaborative Group SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
9. T Kosoglou, P Statkevich, AO Johnson-Levonas, JF Paolini, AJ Bergman, KB Alton Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions Clin Pharmacokinet 44 2005 467 494 (Pubitemid 40733733)
10. C Baigent, M Landray, C Leaper et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease Am J Kidney Dis 45 2005 473 484 (Pubitemid 40341326)
11. M Landray, C Baigent, C Leaper et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD Am J Kidney Dis 47 2006 385 395 (Pubitemid 43255171)
12. SHARP Collaborative Group Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease Am Heart J 160 2010 785 794
13. JM Lang, JE Buring, B Rosner et al. Estimating the effect of the run-in on the power of the Physicians' Health Study Stat Med 10 1991 1585 1593
14. SJ Pocock, R Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
15. R Peto, MC Pike, P Armitage et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part 1: introduction and design Br J Cancer 34 1976 585 612 (Pubitemid 8004970)
16. R Peto, MC Pike, P Armitage et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part 2: analysis and examples Br J Cancer 35 1977 1 39 (Pubitemid 8018922)
17. AS Levey, T Greene, JW Kusek, GJ Beck the MDRD Study Group A simplified equation to predict glomerular filtration from serum creatinine J Am Soc Nephrol 11 2000 155A (abstr A0828).
18. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease Am J Kidney Dis 39 suppl 1 2002 S46 S75
19. C Wanner, V Krane, W März et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248 (Pubitemid 41058323)
20. BC Fellström, AG Jardine, RE Schmieder for the AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
21. H Holdaas, B Fellström, AG Jardine on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 2003 2024 2031 (Pubitemid 36695044)
22. MH Davidson, T McGarry, R Bettis et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia J Am Coll Cardiol 40 2002 2125 2134 (Pubitemid 36005898)
23. AB Rossebø, TR Pedersen, K Boman for the SEAS Investigators Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 2008 1343 1356
24. R Peto, J Emberson, M Landray et al. Analyses of cancer data from three ezetimibe trials N Engl J Med 359 2008 1357 1366
25. CP Cannon, RP Giugliano, MA Blazing for the IMPROVE-IT investigators Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Am Heart J 156 2008 826 832
26. NICE Clinical Guideline 67 Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2008 National Institute for Health and Clinical Excellence London, UK